DCTHDelcath Systems Inc
DCTH
Delcath Systems Inc26,261
Mkt Cap
$381.81MVolume
241,520.0052W High
$18.2352W Low
$8.12PE Ratio
1,843.33DCTH Fundamentals
Price
$11.37Prev Close
$11.06Open
$11.0050D MA
$10.00Beta
1.28Avg. Volume
277,905.19EPS (Annual)
$0.0676P/B
3.38Rev/Employee
$546,352.56$313.09
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New...
Business Wire·6h ago
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
Delcath Systems (DCTH) delivered earnings and revenue surprises of -200.00% and -0.42%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective...
Business Wire·5d ago
Delcath Systems (DCTH) to Release Quarterly Earnings on Thursday
Delcath Systems (NASDAQ:DCTH) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-delcath-systems-inc-stock...
MarketBeat·12d ago
Delcath Systems to Host First Quarter 2026 Earnings Call
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2026...
Business Wire·19d ago
Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by Brokerages
Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the com...
MarketBeat·21d ago
JPMorgan Chase & Co. Decreases Position in Delcath Systems, Inc. $DCTH
JPMorgan Chase & Co. cut its position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 92.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 12,501 shares of the company's stock after selling 155,744 shares during the period. JPMorgan Chase & Co.'s ho...
MarketBeat·23d ago
Delcath Systems (NASDAQ:DCTH) Stock Price Up 0.3% - Time to Buy?
Delcath Systems (NASDAQ:DCTH) Shares Up 0.3% - Should You Buy...
MarketBeat·25d ago
Implied Volatility Surging for Delcath Systems Stock Options
Investors need to pay close attention to DCTH stock based on the movements in the options market lately.
Zacks·1mo ago
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMOEURACAN Clinical Practice Guidelines for Uveal Melanoma
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT Hepatic Delivery System for...
Business Wire·1mo ago
<
1
2
...
>